185 related articles for article (PubMed ID: 20881958)
1. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Kakuda TN; Wade JR; Snoeck E; Vis P; Schöller-Gyüre M; Peeters MP; Corbett C; Nijs S; Vingerhoets J; Leopold L; De Smedt G; Woodfall BJ; Hoetelmans RM
Clin Pharmacol Ther; 2010 Nov; 88(5):695-703. PubMed ID: 20881958
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
[TBL] [Abstract][Full Text] [Related]
4. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
5. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Kakuda TN; Schöller-Gyüre M; Workman C; Arasteh K; Pozniak AL; De Smedt G; Beets G; Peeters M; Vandermeulen K; Woodfall BJ; Hoetelmans RM
Antivir Ther; 2008; 13(5):655-61. PubMed ID: 18771049
[TBL] [Abstract][Full Text] [Related]
6. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
[TBL] [Abstract][Full Text] [Related]
7. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
[TBL] [Abstract][Full Text] [Related]
9. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.
Kakuda TN; Brochot A; Green B; Nijs S; Vis P; Opsomer M; Tomaka FL; Hoetelmans RM
J Clin Pharmacol; 2016 Nov; 56(11):1395-1405. PubMed ID: 27060341
[TBL] [Abstract][Full Text] [Related]
11. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
Hull MW; Montaner JS
Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
; Nadler JP; Berger DS; Blick G; Cimoch PJ; Cohen CJ; Greenberg RN; Hicks CB; Hoetelmans RM; Iveson KJ; Jayaweera DS; Mills AM; Peeters MP; Ruane PJ; Shalit P; Schrader SR; Smith SM; Steinhart CR; Thompson M; Vingerhoets JH; Voorspoels E; Ward D; Woodfall B
AIDS; 2007 Mar; 21(6):F1-10. PubMed ID: 17413684
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Katlama C; Clotet B; Mills A; Trottier B; Molina JM; Grinsztejn B; Towner W; Haubrich R; Nijs S; Vingerhoets J; Woodfall B; Witek J
Antivir Ther; 2010; 15(7):1045-52. PubMed ID: 21041921
[TBL] [Abstract][Full Text] [Related]
15. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.
Königs C; Feiterna-Sperling C; Esposito S; Viscoli C; Rosso R; Kakuda TN; Leemans R; Peeters M; Mack R; Peeters I; Sinha R; Boven K; Giaquinto C
AIDS; 2012 Feb; 26(4):447-55. PubMed ID: 22156961
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
[TBL] [Abstract][Full Text] [Related]
18. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
Tudor-Williams G; Cahn P; Chokephaibulkit K; Fourie J; Karatzios C; Dincq S; Opsomer M; Kakuda TN; Nijs S; Tambuyzer L; Tomaka FL;
HIV Med; 2014 Oct; 15(9):513-24. PubMed ID: 24589294
[TBL] [Abstract][Full Text] [Related]
19. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.
Green B; Crauwels H; Kakuda TN; Vanveggel S; Brochot A
Clin Pharmacokinet; 2017 May; 56(5):525-536. PubMed ID: 27665573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
